Prescription drug pricing needs to change, panelists say
Perhaps the last issue in the U.S. that people of all political persuasions can agree on is that prescription drug prices are too high.
That’s according to Sarah Emond, president and CEO of the Institute for Clinical and Economic Review. She was one of a panel of experts who discussed drug affordability during the AHIP Medicare, Medicaid, Duals and Commercial Markets Forum in Washington.
She called for policymakers to come up with solutions “to voluntarily de-escalate where we are with drug pricing.”
“We can make different choices,” she said. “The status quo is harming patient affordability.”
“We’re in a place where, because of pressures on the pharmaceutical industry, the industry is rethinking its pricing policies,” said Robert Popovian, founder of Conquest Advisors and senior health policy visiting fellow at Pioneer Institute. “It is a positive step because we don’t want regulators doing it for them.”
Right to negotiate
The Inflation Reduction Act gave the federal government the ability to negotiate prices for certain high‑cost prescription drugs covered by Medicare. The negotiated price produced by that process is legally called the Maximum Fair Price. This practice was previously prohibited by the Medicare “non‑interference” clause.
Negotiation applies to single‑source brand drugs with no generic or biosimilar competition. The first round covers 10 Medicare Part D drugs, with negotiated prices effective Jan. 1, 2026. The number of negotiated drugs grows over time:
-
- 15 drugs in 2027
- 15 more in 2028
- 20 drugs per year beginning in 2029
The Centers for Medicare and Medicaid Services estimates that the first 10 negotiated drugs will reduce Medicare spending by about $6 billion annually, based on 2023 utilization volumes. Some negotiated prices are 40–60% lower than prior list prices.
The IRA “created an environment where we know what the net prices of drugs are,” Popovian said. “It will put pressure on entities that make money on margins. Pharmaceutical companies won’t be in bad shape after the IRA – it’s all the other entities that make money on margins that will be affected.”
Maximum fair pricing “will help consumers,” Popovian said. “And, no doubt, the $2,000 cap on out-of-pocket prescription drugs under the IRA helped Medicare Part D consumers.”
“The pharmaceutical industry knows things have to change,” Emond said. “They’re ready to make changes.”
© Entire contents copyright 2026 by InsuranceNewsNet.com Inc. All rights reserved. No part of this article may be reprinted without the expressed written consent from InsuranceNewsNet.com.
Susan Rupe is editor in chief, magazine, for InsuranceNewsNet. She formerly served as communications director for an insurance agents' association and was an award-winning newspaper reporter and editor. Contact her at susan.rupe@innfeedback.com.



Corebridge, Equitable merge to create potential new annuity sales king
CMS seeks stability in the Medicare market
Advisor News
- Survey: Most Americans still feel prosperous despite economic worries
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
More Annuity NewsHealth/Employee Benefits News
- Grand jury accuses veteran of making false disability claims that defrauded VA
- States push short-term insurance as healthcare costs climb
- Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
- Two May Work for You As One
- AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
More Health/Employee Benefits NewsLife Insurance News
- AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
- AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
- AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
- AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
- AM Best Upgrades Credit Ratings of CTBC Insurance Company Ltd
More Life Insurance News